Laurus Labs shares zoom over 7%: Here is why the pharma stock touched 52-week high today

Last week, the pharma company recorded robust June quarter earnings for the financial year 2025-26. The firm also reported a third straight quarter of margin increasing above 20%.

Laurus Labs’ net profit increased 1,154% for Q1 FY26 at ₹163 crore in contrast to ₹13 crore a year ago. The firm's revenue grew 31% to ₹1,570 crore in Q1FY26 as against ₹1,195 crore in Q1FY25.

The growth was fuelled by increasing uptake in CDMO deliveries and healthy business fundamentals.

Its Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) rose 127% year-on-year (YoY) to ₹389 crore compared to ₹171 crore clocked in the same quarter of the previous fiscal year.

Margin for the quarter stood at 24.8% during the quarter under review, supported by continuing operating leverage as against 14.3% YoY.

Gross margins stood strong at 59.4% due to a favourable CDMO mix and ongoing process improvement initiatives.

“We made healthy progress to start the year with increasing contributions from the CDMO business and continued advancement of pipeline projects, supported by Generic FDF. We are moving ahead with a strong focus on commercial execution, realising the full potential from promising pipeline opportunities, business development, and rapidly enhancing scale and technology capabilities,” said Dr. Satyanarayana Chava, Founder & Chief Executive Officer.

“We remain confident in our strategic direction and commitment as the source of sustainable value creation now and well into the future,” Chava further said.

Last seen, the stock was trading at ₹891.75 per share on NSE, soaring 6.45%.

Besides, the Government of Andhra Pradesh on Sunday allotted 531.77 acres of land in Anakapalli district to Laurus Labs for its new plant. The new unit will be used for manufacturing pharma products.

The company has projected ₹5,630 crore of investment and plans to provide employment to 6,350 people in three phases over a period of eight years. “With this allotment, the Company has secured an important component for future expansion of its business, i.e., a land parcel,” Laurus Labs said in a statement.